UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$950M |
| 2 |
Linde
LIN
|
+$886M |
| 3 |
Amgen
AMGN
|
+$812M |
| 4 |
Pinduoduo
PDD
|
+$400M |
| 5 |
Advanced Micro Devices
AMD
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ametek
AME
|
+$475M |
| 2 |
Microsoft
MSFT
|
+$266M |
| 3 |
Amazon
AMZN
|
+$221M |
| 4 |
VMW
VMware, Inc
VMW
|
+$197M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$140M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.09% |
| 2 | Healthcare | 14.47% |
| 3 | Financials | 11.11% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2376
Accel Entertainment
ACEL
$987M
| $335K | ﹤0.01% |
36,827
| – | – |
|
2377
Lexicon Pharmaceuticals
LXRX
$1.1B
| $335K | ﹤0.01% |
137,735
+18,689
| +16% | +$42.8K |
|
2378
Select Water Solutions
WTTR
$2.61B
| $334K | ﹤0.01% |
48,042
-9,804
| -17% | -$76.3K |
|
|
HCCI
2379
DELISTED
Heritage-Crystal Clean, Inc.
HCCI
| $334K | ﹤0.01% |
9,388
+1,554
| +20% | +$56K |
|
2380
ImmunityBio
IBRX
$8.1B
| $333K | ﹤0.01% |
182,930
+35,732
| +24% | +$111K |
|
2381
Hackett Group
HCKT
$287M
| $332K | ﹤0.01% |
17,952
-19,608
| -52% | -$395K |
|
2382
Movado Group
MOV
$841M
| $331K | ﹤0.01% |
11,502
-8,206
| -42% | -$278K |
|
2383
Scholar Rock
SRRK
$6.44B
| $330K | ﹤0.01% |
41,287
+5,508
| +15% | +$55.9K |
|
|
NUTX
2384
Nutex Health
NUTX
$1.11B
| $329K | ﹤0.01% |
2,173
| – | – |
|
|
AGTI
2385
DELISTED
Agiliti Inc
AGTI
| $329K | ﹤0.01% |
20,585
+3,272
| +19% | +$56.3K |
|
2386
Donegal Group Class A
DGICA
$714M
| $329K | ﹤0.01% |
21,527
| – | – |
|
2387
Tredegar Corp
TG
$310M
| $327K | ﹤0.01% |
35,857
+9,953
| +38% | +$110K |
|
|
VERV
2388
DELISTED
Verve Therapeutics
VERV
| $325K | ﹤0.01% |
22,515
+1,160
| +5% | +$22.7K |
|
2389
Traeger
COOK
$172M
| $324K | ﹤0.01% |
1,576
| – | – |
|
|
LX
2390
LexinFintech Holdings
LX
$241M
| $323K | ﹤0.01% |
119,295
| – | – |
|
2391
Smith & Wesson
SWBI
$637M
| $323K | ﹤0.01% |
26,243
-234
| -0.9% | -$2.5K |
|
2392
Future Fuel
FF
$223M
| $321K | ﹤0.01% |
43,505
| – | – |
|
|
ICPT
2393
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $320K | ﹤0.01% |
23,834
-3,745
| -14% | -$64.8K |
|
2394
Clearwater Paper
CLW
$376M
| $319K | ﹤0.01% |
9,555
| – | – |
|
2395
ARKO Corp
ARKO
$635M
| $317K | ﹤0.01% |
+37,382
| New | +$312K |
|
|
EQRX
2396
DELISTED
EQRx, Inc. Common Stock
EQRX
| $316K | ﹤0.01% |
163,061
+1,479
| +0.9% | +$3.37K |
|
2397
CarParts.com
PRTS
$54.7M
| $315K | ﹤0.01% |
5,906
+386
| +7% | +$24.5K |
|
|
ROVR
2398
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $315K | ﹤0.01% |
69,580
+16,180
| +30% | +$65.2K |
|
|
NNDM
2399
Nano Dimension
NNDM
$343M
| $314K | ﹤0.01% |
+108,711
| New | +$292K |
|
2400
Atara Biotherapeutics
ATRA
$76.1M
| $313K | ﹤0.01% |
+4,320
| New | +$419K |
|
Similar funds
UBS AM's Q1 2023 Portfolio in Review
As of Q1 2023, UBS AM held 2,762 positions worth $206B, up 8.3% from $191B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
UBS AM's Q1 2023 filing shows 231 new, 1,328 increased, 856 reduced and 85 closed positions. Its largest new stake was Amgen: 3,308,425 shares worth $800M. The largest sale was Ametek, an estimated $475M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q1 2023 buy was Amgen: 3,308,425 shares worth $800M.
- UBS AM added most to Abbott in Q1 2023, an estimated $950M increase.
- UBS AM's biggest Q1 2023 reduction was Ametek, cutting an estimated $475M.
- UBS AM fully exited SVB Financial Group in Q1 2023, selling an estimated $77.3M.
- UBS AM's ten largest holdings make up 22% of its $206B portfolio in Q1 2023.
- UBS AM opened 231 new positions and closed 85 in Q1 2023.
- UBS AM's portfolio value rose 8.3% quarter-over-quarter to $206B.
Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.